YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue clim…
Activists also report to the SEC on Allot Communications, Genco Shipping & Trading, Aurinia Pharmaceuticals, and Turtle Beach. Continue Reading
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia's patents covering its flagship oral…
Aurinia Pharmaceuticals AUPH announced that it, along with the U.S. subsidiary, has entered into a settlement agreement with Teva Pharmaceuticals TEVA to resolve patent infringement litigation related to the latter's abbreviated new drug a…
Aurinia Pharmaceuticals Inc. recently reported second-quarter 2026 results showing higher revenue and earnings year over year, reiterated its 2026 revenue and net product sales guidance, completed a large share buyback program, and finaliz…
[Intellectual Property] stocknshares * Teva Pharmaceutical Industries (TEVA [https://seekingalpha.com/symbol/TEVA]) will not be able to launch a generic version of Aurinia Pharmaceuticals' (AUPH [https://seekingalpha.com/symbol/AUPH]) Lupk…
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-rec…
Is AUPH a good stock to buy? We came across a bullish thesis on Aurinia Pharmaceuticals Inc. on BioEquity Watch's Substack. In this article, we will summarize the bulls' thesis on AUPH. Aurinia Pharmaceuticals Inc.'s share was trading at $…
Aurinia Pharmaceuticals (AUPH) shares ended the last trading session 6.5% higher at $17.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.2%…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns…
Activists also report to the SEC on Victoria’s Secret, Dell Technologies, Valaris, and Universal Technical Institute. Continue Reading
Kevin Tang, Chief Executive Officer of Aurinia Pharmaceuticals Inc.(NASDAQ:AUPH), reported the purchase of 814,606 common shares across multiple transactions between May 29, 2026, and June 2, 2026, according to a SEC Form 4 filing. Transac…
Key Points 814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang’s total holdings prior to the transa…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY) one of those stocks right now? A quick glance at the company's year-to-…
* Tang Capital Management Tuesday said that it acquired [https://seekingalpha.com/pr/20538103-tang-capital-management-llc-files-early-warning-report-respecting-aurinia-pharmaceuticals-inc]206,005 common shares of Aurinia Pharmaceuticals (A…
Select Medical (SEM) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items.…
ARS Pharmaceuticals, Inc. (SPRY) shares soared 7.1% in the last trading session to close at $8.4. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4% gain over t…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts across therapeutic areas like Psoriasis, Asthma, C…
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California, March 30, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with auto…
Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition. Continue Reading
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's…
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading
The Relative Strength (RS) Rating for KalVista Pharmaceuticals stock entered a new percentile Wednesday, with a rise from 79 to 86. Decades of market research shows that the best-performing stocks typically have an 80 or higher RS Rating a…
Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading
Xenon Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is one of the best cheap biotech stocks to buy now. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and twelve months ended December 31, 2025, on February 26, 2…
Aurinia Pharmaceuticals logo Key Points LUPKYNIS-driven growth and 2026 guidance: Q4 revenue rose to $77.1M (+29%) and full-year 2025 revenue was $283.1M (+20%; +26% excluding a $10M Japan milestone) with LUPKYNIS sales of $271.3M, and man…
Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VISN]) *…
United Therapeutics (UTHR) came out with quarterly earnings of $7.7 per share, beating the Zacks Consensus Estimate of $6.78 per share. This compares to earnings of $6.19 per share a year ago. These figures are adjusted for non-recurring i…
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading
Xenon Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating Continue Reading
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $1 per share a year ago. These figures are adjusted for non-recurring…
A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue? Continue Reading
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aurinia Pharmaceuticals (AUPH) been one of those stocks this year? By taking a look at the stock's year-to-date perform…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aurinia Pharmaceuticals (AUPH) is a stock that can certainly grab the attention of many investors, but do its recent return…
[Financial term Small Capitalization Stocks on gray and red finance background from graphs, charts. Trend Up and Down, Flat. 3D render] Vladimir Zakharov/iStock via Getty Images The Russell 2000 index (RTY [https://seekingalpha.com/symbol/…